

GLAXOSMITHKLINE PLC

Form 6-K

July 14, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 14 July 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley  
 b) Position/status Chief Executive Officer

- c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

- b) Nature of the transaction ISIN: GB0009252882  
 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017.

- c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £16.2649 379.126  
 n/a (single transaction)

- d) Aggregated information  
 Aggregated volume Price

- e) Date of the transaction 2017-07-13  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor  
 b) Position/status President, Global Manufacturing & Supply

- c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence  
 each ('Ordinary Shares')

b) Nature of the transaction ISIN: GB0009252882  
 Acquisition of Ordinary  
 Shares following the  
 re-investment of dividends  
 paid to shareholders on 13  
 July 2017.

c) Price(s) and volume(s) Price(s) Volume(s)  
 £16.2649 341.077  
 n/a (single transaction)

Aggregated information  
 d) Aggregated volume Price

e) Date of the transaction 2017-07-13  
 f) Place of the transaction London Stock Exchange  
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr L Debruyne  
 b) Position/status President, Global Vaccines  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction  
 platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence  
 each ('Ordinary Shares')

b) Nature of the transaction ISIN: GB0009252882  
 Acquisition of Ordinary  
 Shares following the  
 re-investment of dividends  
 paid to shareholders on 13  
 July 2017.

c) Price(s) and volume(s) Price(s) Volume(s)  
 £16.2649 911.961

d) Aggregated information n/a (single transaction)

Aggregated volume Price

- e) Date of the transaction 2017-07-13  
 f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')  
 a) Name Mr S Dingemans  
 b) Position/status Chief Financial Officer  
 c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  
 a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017.
- c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £16.2649 736.599  
 n/a (single transaction)

Aggregated information

- d) Aggregated volume Price
- e) Date of the transaction 2017-07-13  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')  
 a) Name Mr S A Hussain  
 b) Position/status President, Global Pharmaceuticals  
 c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  
 a) Name GlaxoSmithKline plc

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence  
 each ('Ordinary Shares')

b) Nature of the transaction ISIN: GB0009252882  
 Acquisition of Ordinary  
 Shares following the  
 re-investment of dividends  
 paid to shareholders on 13  
 July 2017.

c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £16.2649 15.986  
 n/a (single transaction)

Aggregated information  
 d) Aggregated volume Price

e) Date of the transaction 2017-07-13  
 f) Place of the transaction London Stock Exchange  
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern  
 b) Position/status Chief Strategy Officer  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction  
 platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence  
 each ('Ordinary Shares')

b) Nature of the transaction ISIN: GB0009252882  
 Acquisition of Ordinary  
 Shares following the  
 re-investment of dividends  
 paid to shareholders on 13  
 July 2017.

c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £16.2649 1,243.403

d) Aggregated information n/a (single transaction)

Aggregated volume Price

- e) Date of the transaction 2017-07-13  
 f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')  
 a) Name Ms C Thomas  
 b) Position/status SVP, HR  
 c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  
 a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017.
- c) Price(s) and volume(s)  

Price(s)	Volume(s)
£16.2649	445.495
n/a (single transaction)	

Aggregated information

- d) Aggregated volume Price
- e) Date of the transaction 2017-07-13  
 f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')  
 a) Name Mr P C Thomson  
 b) Position/status President, Global Affairs  
 c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence  
 each ('Ordinary Shares')  
 ISIN: GB0009252882  
 Acquisition of Ordinary  
 Shares following the  
 b) Nature of the transaction re-investment of dividends  
 paid to shareholders on 13  
 July 2017.  
 c) Price(s) and volume(s) Price(s) Volume(s)  
 £16.2649 583.338  
 n/a (single transaction)

- Aggregated information  
 d) Aggregated volume Price

- e) Date of the transaction 2017-07-13  
 f) Place of the transaction London Stock Exchange  
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Dr P J T Vallance  
 b) Position/status President, R&D  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction  
 platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence  
 each ('Ordinary Shares')  
 ISIN: GB0009252882  
 Acquisition of Ordinary  
 Shares following the  
 b) Nature of the transaction re-investment of dividends  
 paid to shareholders on 13  
 July 2017.  
 c) Price(s) and volume(s) Price(s) Volume(s)  
 £16.2649 2,337.700  
 d) Aggregated information n/a (single transaction)

A

Aggregated volume Price

- e) Date of the transaction 2017-07-13  
 f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')  
 a) Name Mrs K Thomson  
 b) Position/status PCA of Mr P C Thomson (President, Global Affairs)  
 c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  
 a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017.
- c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £16.2649 110.180  
 n/a (single transaction)

Aggregated information

- d) Aggregated volume Price

- e) Date of the transaction 2017-07-13  
 f) Place of the transaction London Stock Exchange (XLON)

SIGNATURES



Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: July 14, 2017

By: VICTORIA WHYTE

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc